Zoetis (ZTS) Financials: History & Chart

Zoetis Inc. (ZTS)ZTSZoetis Inc.

About Zoetis Inc.

Zoetis Inc. stands as a global leader in animal health, focusing on the research, development, manufacturing, and commercialization of veterinary pharmaceuticals, vaccines, and diagnostic tools. Its comprehensive portfolio serves a broad spectrum of species, encompassing both livestock, including cattle, swine, poultry, fish, and sheep, and beloved companion animals such as dogs, cats, and horses. Among its pharmaceutical offerings are various therapeutic agents. This includes vaccines, vital for preventing respiratory, gastrointestinal, and reproductive diseases by stimulating a targeted immune response; anti-infectives that combat or inhibit the proliferation of bacterial, fungal, or protozoal pathogens; and parasiticides aimed at eradicating both internal and external pests such as fleas, ticks, and various worms. Additional pharmaceuticals address areas such as pain management and sedation, anti-emesis, reproductive health, and oncology. The portfolio also features dermatological solutions for allergic skin conditions and atopic dermatitis, alongside medicated feed additives specifically designed for livestock. Beyond therapeutics, Zoetis offers an extensive array of diagnostic solutions. These include portable analysis systems for blood and urine, point-of-care testing devices, specialized instruments and reagents, rapid immunoassay kits, comprehensive reference laboratory services, and blood glucose monitoring equipment. Further extending its reach, the company provides supplementary offerings such as nutritional products, agribusiness support services, biodevices, genetic testing, and innovations in precision animal health. Zoetis distributes its diverse product portfolio to a broad customer base, including veterinary professionals, livestock producers, and retail channels. This distribution occurs directly via its sales representatives and technical specialists, as well as through partnerships with third-party veterinary distributors. Established in 1952, the company maintains its corporate headquarters in Parsippany, New Jersey.

Parsippany, NJ

14,500 employees

www.zoetis.com

Healthcare / Drug Manufacturers - General

Sector: Healthcare
Industry: Drug Manufacturers - General
CEO: Kristin C. Peck

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024	Quarter ended Jun 2024
Revenue	9.51B	2.26B	2.39B	2.40B	2.46B	2.22B	2.32B	2.39B	2.36B
Cost of Goods Sold	2.78B	641.00M	743.00M	715.00M	682.00M	654.00M	741.00M	736.00M	703.00M
Gross Profit	6.73B	1.62B	1.64B	1.69B	1.78B	1.57B	1.58B	1.65B	1.66B
Gross Profit Margin	70.8%	71.7%	68.9%	70.2%	72.3%	70.5%	68.0%	69.2%	70.2%
Total Operating Expenses	3.15B	799.00M	818.00M	749.00M	789.00M	720.00M	811.00M	732.00M	752.00M
Research & Development	721.00M	180.00M	199.00M	170.00M	172.00M	157.00M	186.00M	167.00M	171.00M
Selling, General & Administrative	2.40B	588.00M	619.00M	579.00M	617.00M	563.00M	625.00M	565.00M	581.00M
Operating Income (EBIT)	3.57B	822.00M	826.00M	936.00M	989.00M	846.00M	765.00M	920.00M	906.00M
Operating Margin	37.6%	36.3%	34.6%	39.0%	40.2%	38.1%	33.0%	38.5%	38.4%
Income Before Tax (EBT)	3.31B	758.00M	761.00M	887.00M	902.00M	810.00M	732.00M	874.00M	780.00M
Interest Income	91.00M	21.00M	25.00M	26.00M	19.00M	23.00M	27.00M	23.00M	24.00M
Interest Expense	241.00M	62.00M	57.00M	64.00M	58.00M	59.00M	56.00M	61.00M	63.00M
Other Income/Expense	-265.00M	-64.00M	-65.00M	-49.00M	-87.00M	-36.00M	-33.00M	-46.00M	-126.00M
Net Income	2.64B	601.00M	603.00M	721.00M	718.00M	631.00M	581.00M	682.00M	624.00M
Income Tax Expense	665.00M	157.00M	158.00M	166.00M	184.00M	179.00M	151.00M	182.00M	156.00M
Net Profit Margin	27.8%	26.6%	25.3%	30.0%	29.2%	28.4%	25.1%	28.6%	26.4%
EBITDA	4.06B	941.00M	947.00M	1.06B	1.11B	965.00M	888.00M	1.04B	1.03B
EBITDA Margin	42.7%	41.6%	39.7%	44.2%	45.2%	43.5%	38.3%	43.6%	43.8%
Depreciation & Amortization	487.00M	119.00M	121.00M	124.00M	123.00M	119.00M	123.00M	121.00M	127.00M
EPS Basic	6.04	1.42	1.38	1.63	1.61	1.41	1.29	1.51	1.37
EPS Diluted	6.03	1.42	1.37	1.63	1.61	1.41	1.29	1.50	1.37
Shares Outstanding	422.10M	422.10M	438.20M	442.90M	445.10M	447.60M	450.50M	452.90M	455.50M
Diluted Shares Outstanding	422.40M	422.40M	438.60M	443.20M	445.50M	448.00M	451.10M	453.50M	456.00M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	9.47B	9.26B	8.54B	8.08B	7.78B	6.67B	6.26B	5.83B
Cost of Goods Sold	2.79B	2.86B	2.71B	2.60B	2.46B	2.22B	2.15B	2.03B
Gross Profit	6.67B	6.40B	5.83B	5.48B	5.31B	4.46B	4.11B	3.80B
Gross Profit Margin	70.5%	69.1%	68.3%	67.8%	68.3%	66.8%	65.7%	65.2%
Total Operating Expenses	3.08B	3.00B	2.77B	2.55B	2.51B	2.19B	2.10B	1.92B
Research & Development	698.00M	686.00M	614.00M	539.00M	508.00M	463.00M	457.00M	432.00M
Selling, General & Administrative	2.38B	2.32B	2.15B	2.01B	2.00B	1.73B	1.64B	1.48B
Operating Income (EBIT)	3.60B	3.39B	3.07B	2.93B	2.80B	2.27B	2.02B	1.88B
Operating Margin	38.0%	36.6%	35.9%	36.2%	36.0%	34.0%	32.2%	32.3%
Income Before Tax (EBT)	3.36B	3.13B	2.94B	2.66B	2.49B	2.00B	1.80B	1.69B
Interest Income	93.00M	106.00M	105.00M	50.00M	6.00M	12.00M	37.00M	31.00M
Interest Expense	243.00M	242.00M	258.00M	237.00M	236.00M	249.00M	242.00M	212.00M
Other Income/Expense	-237.00M	-259.00M	-133.00M	-272.00M	-315.00M	-273.00M	-217.00M	-191.00M
Net Income	2.67B	2.49B	2.34B	2.11B	2.04B	1.64B	1.50B	1.43B
Income Tax Expense	687.00M	637.00M	596.00M	545.00M	454.00M	360.00M	301.00M	266.00M
Net Profit Margin	28.2%	26.9%	27.4%	26.2%	26.2%	24.5%	24.0%	24.5%
EBITDA	4.08B	3.89B	3.56B	3.39B	3.25B	2.71B	2.43B	2.19B
EBITDA Margin	43.1%	42.0%	41.7%	42.0%	41.8%	40.6%	38.8%	37.6%
Depreciation & Amortization	487.00M	497.00M	491.00M	465.00M	448.00M	441.00M	412.00M	308.00M
EPS Basic	6.03	5.47	5.08	4.51	4.29	3.44	3.14	2.96
EPS Diluted	6.02	5.47	5.07	4.49	4.27	3.42	3.11	2.93
Shares Outstanding	443.44M	454.20M	461.17M	468.89M	474.35M	475.50M	478.13M	483.06M
Diluted Shares Outstanding	443.83M	454.85M	462.27M	470.38M	476.72M	478.57M	481.79M	486.90M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.